At 32.3% CAGR, the Asia Pacific Vitamin K2 Market is projected to be worth US$ 187.93 million by 2030, says Business Market Insights

According to Business Market Insights research, the Asia Pacific vitamin K2 market was valued at US$ 20.05 million in 2022 and is expected to reach US$ 187.93 million by 2030, registering a CAGR of 32.3% from 2022 to 2030. Regulatory consideration and standards and growing cases of osteoporosis bone deformation in adults and newborns are among the critical factors attributed to the Asia Pacific vitamin K2 market expansion.

Osteoporosis is an increasingly common health issue affecting adults and babies, a disorder marked by weakening and fragile bones. According to International Osteoporosis Foundation 2022, globally osteoporosis causes more than 8.9 million fractures every year resulting in osteoporotic fracture in every 3 seconds. Medical professionals are concerned about the surge in osteoporosis-related bone distortion cases. As per recent studies from Research Gate, the potential advantages of vitamin K2 include supporting bone health and possibly reducing the consequences of osteoporosis.

Vitamin K2 is a lesser-known vitamin K essential for maintaining healthy calcium metabolism and bone density. It stimulates proteins that transfer calcium from the bloodstream into the bones to ensure adequate mineralization and strength. The nutrient aid in avoiding osteoporosis-related bone fractures and deformities by improving calcium absorption. Adult osteoporosis cases frequently result from hormonal changes, age-related bone loss, or inadequate food intake. Vitamin K2 supplementation has demonstrated promising outcomes in enhancing bone mineral density and lowering fracture risk among adults. In addition, women are the main target for bone health products due to their higher incidence of osteoporosis. The increasing incidence of osteoporosis-related difficulties continues to be a key focus for functional foods and supplements such as calcium and vitamin D are the primary components supporting bone health. Calcium is the main mineral component of bones, while vitamin helps with calcium absorption. changes However, as consumers are becoming more aware of the benefits of vitamin K2, its availability in foods and supplements is rising. In addition, it has been proposed that vitamin K2 aids in reducing the activity of osteoclast cells, which are responsible for bone deterioration, further protecting bone integrity.

Newborns can develop osteoporosis, especially preterm babies. They are more prone to fractures since their bones are immature and weak. Vitamin K2 improves bone growth and lessens the likelihood of bone abnormalities in the therapy regimens for these infants. Their skeletal development is accelerated by vitamin K2 supplementation, which supports the naturally occurring processes during the early stages of life. Thus, the growing number of adult and neonatal incidences of osteoporosis-related bone abnormalities creates the urgent need for efficient preventative measures and treatment approaches. Hence, vitamin K2 supplementation acts as a potential supplementary therapy that helps with calcium metabolism, bone mineralization, and the prevention of fractures. All these factors are driving the market growth.

On the contrary, limited awareness regarding benefits of vitamin K2 hampers the Asia Pacific vitamin K2 market.

Based on product, the Asia Pacific vitamin K2 market is segmented into MK-4, MK-7, and combination drugs. The MK-7 segment held 65.1% share of Asia Pacific vitamin K2 market in 2022, amassing US$ 13.06 million. It is projected to garner US$ 124.60 million by 2030 to expand at 32.6% CAGR during 2022-2030.

Based on dosage forms, the Asia Pacific vitamin K2 market is segmented into capsules & tablets, powder, and oils. The powder segment held 57.9% share of Asia Pacific vitamin K2 market in 2022, amassing US$ 11.61 million. It is projected to garner US$ 112.57 million by 2030 to expand at 32.8% CAGR during 2022-2030.

Based on source, the Asia Pacific vitamin K2 market is segmented into natural and synthetic. The natural segment held 84.2% share of Asia Pacific vitamin K2 market in 2022, amassing US$ 16.87 million. It is projected to garner US$ 159.66 million by 2030 to expand at 32.4% CAGR during 2022-2030.

Based on application, the Asia Pacific vitamin K2 market is segmented into pharmaceuticals, nutraceuticals and food, and others. The pharmaceuticals segment held 65.9% share of Asia Pacific vitamin K2 market in 2022, amassing US$ 13.22 million. It is projected to garner US$ 120.84 million by 2030 to expand at 31.9% CAGR during 2022-2030.

Based on country, the Asia Pacific vitamin K2 market has been categorized into the China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that the Rest of Asia Pacific captured 26.9% share of Asia Pacific vitamin K2 market in 2022. It was assessed at US$ 5.40 million in 2022 and is likely to hit US$ 51.79 million by 2030, exhibiting a CAGR of 32.7% during 2022-2030.

Key players operating in the Asia Pacific vitamin K2 market are Balchem Corp, BASF SE, Glanbia Plc, International Flavors & Fragrances Inc, Koninklijke DSM NV, Lesaffre et Cie SA, Lonza Group AG, Novozymes AS, and Seebio Biotech (Shanghai) Co Ltd, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com